Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming…
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (“Cybin”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive…
At City of Hope, Arthur Riggs, Ph.D., and colleagues first developed the technology to create synthetic human insulin, used today…
– 11 New Partnerships Added – – 50 Milestones Achieved – – More than 360 Total Therapeutic Programs at Year-End…
TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company“) today announced that it has entered into an Equity…
TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company“) today announced that it has entered into an Equity…
TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the “Company“) today announced that it has entered into an Equity…
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in…
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in…